1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Ms E Walmsley
| |||
b)
|
Position/status
|
Chief Executive Officer
| |||
c)
|
Initial notification/amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 July 2021 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period
| |||
c)
|
Price(s) and volume(s)
| ||||
Price(s)
|
Volume(s)
| ||||
£14.2600
|
8,484.786
| ||||
d)
|
Aggregated information
Aggregated volume
Price
|
N/A (single transaction)
| |||
e)
|
Date of the transaction
|
2021-07-12
| |||
f)
|
Place of the transaction |
London Stock Exchange (XLON)
|
Attachments
- Original document
- Permalink
Disclaimer
GSK - GlaxoSmithKline plc published this content on 14 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 July 2021 16:04:05 UTC.